Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
BioSure HIV Self Test allows for private testing in a time and place convenient to the user. The test is discreetly delivered in the post and once everything is finished all the testing equipment can be thrown away in the bag provided with the usual rubbish.
days to go:
Expired
investment:
£495,459
freemarketFX is an FCA authorised, innovative peer-to-peer currency exchange, focused on the high-value B2B commercial spot FX market.
days to go:
Expired
investment:
£645,496
The Fitfck application (parented by The Social Station Media Group) is a fitness dating app designed to connect like-minded fitness enthusiasts within a socially isolating lifestyle. The app is based on the founders' experience and has been described as 'The UK's fastest-growing fitness social app' by Google, London. The company witnessed 100,000 sign-ups in its first year at a cost per install of £0.30 (Industry average £1.20), has working relationships with Google, Facebook and YouTube, and is available to interested franchisees in 30+ countries. The application has 60,000+ followers across social media handles such as Instagram, Facebook, and Twitter. It has been featured in publications such as Daily Mail, Metro, and London Loves Business. It will use the investment to pay salaries to its staff, increase marketing initiatives, manage server costs, and other expenses.
days to go:
Expired
investment:
Withheld
Peerport Limited (trading as MultiISA) is targeting the multi-million-pound market and claims to offer a holistic approach to Individual Savings Account (ISA) management. The company asserts that traditional ISA managers don’t give users enough flexibility with their investment choices. Current ISA rules restrict investors to only one ISA of each type per tax year. This impedes the investors’ ability to build a diversified IFISA portfolio. Peerport argues that its portal offers investors the freedom to operate multiple accounts like Innovative Finance ISA (IFISA), Cash ISA, and Stocks & Shares ISA under a single ISA management platform. The company will use the investment to finalise the build-out of its end to end platform, fund its office space, manage marketing costs, oversee staffing costs, pay regulatory fees and supervise working capital.
days to go:
Expired
investment:
£6,033
Future Planet is an investor-led, co-investment platform giving entrepreneurs a reliable and profitable platform to solve the world's greatest challenges like health, climate change, education, sustainable growth & security. Until now, venture capital has been accessible mostly to insiders, institutions and some high-net-worth individuals (HNWI's) but Future Planet is democratising this stage of investment. It allows world-renowned institutions such as Tel Aviv University, Stanford University and Cambridge University and more to have a stake in Future Planet and access the growth generated by its participating companies in Silicon Valley, the Eastern Seaboard, Europe, Israel and Asia. Since its founding, the company has brought $100 million from some of the world's largest investors, raised and invested its first fund and invested with important companies and renowned managers. The company plans to use the investment and momentum to launch the second Future Planet Fund in 2021 and continue its growth with a target of $500 million in Assets Under Management (AUM) by 2025.
days to go:
Expired
investment:
£1,553,118
WhiskyInvestDirect leverages BullionVault’s proven model of crowdfunding wholesale bullion bars (25,000 UK clients) and applies it to maturing whisky. The model eliminates the key working capital constraint experienced by producers, whilst users can potentially profit as the whisky increases in value. The team includes the founder and CEO of BullionVault and an ex-Commercial Director at Diageo who has been building whisky brands for the last 24 years.
days to go:
Expired
investment:
£1,076,472
